Propanc Biopharma AI Stock Analysis
Want to see PPCB full AI Analyst Report?
Propanc Biopharma (PPCB) AI Stock Analysis
Propanc Biopharma
(NASDAQ:PPCB)
The overall score of 37 reflects a company in severe financial and market distress. The most significant factors are the complete absence of revenue combined with rapidly escalating operating losses and cash burn, which threaten the company's viability. This is compounded by overwhelmingly bearish technical trends and a recent Nasdaq delisting notice that further jeopardizes its market position. The lack of positive earnings or valuation metrics provides no counterbalance to these critical weaknesses.
Propanc Biopharma (PPCB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 188.00K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.86
- Revenue Growth
- ―
- EPS Growth
- 98.51%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Propanc Biopharma Business Overview & Revenue Model
Company Description
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic c...
Propanc Biopharma Financial Statement Overview
Summary
Financial performance is critically weak. The company has zero revenue, escalating operating losses (TTM EBIT of -$22.1M), and a severe cash burn rate (TTM operating cash flow of -$5.7M). While the balance sheet shows improved equity and negligible debt, the unsustainable consumption of assets and lack of any revenue generation dominate the profile, resulting in the lowest possible score.
Income Statement
1Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6,377 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -22.45M | -18.41M | -58.34M | -1.26M | -2.26M | -2.14M |
| Net Income | -22.61M | -18.86M | -58.92M | -1.82M | -2.66M | -2.66M |
Balance Sheet | ||||||
| Total Assets | 10.33M | 12.78M | 19.63M | 72.36K | 60.33K | 81.65K |
| Cash, Cash Equivalents and Short-Term Investments | 258.37K | 832.01K | 12.09K | 21.09K | 10.05K | 4,067 |
| Total Debt | 42.74K | 48.31K | 1.73M | 948.27K | 545.92K | 1.04M |
| Total Liabilities | 3.26M | 3.38M | 5.73M | 3.85M | 3.18M | 3.11M |
| Stockholders Equity | 7.07M | 9.40M | 13.91M | -3.78M | -3.12M | -3.02M |
Cash Flow | ||||||
| Free Cash Flow | -5.72M | -5.68M | -405.17K | -935.12K | -1.11M | -1.44M |
| Operating Cash Flow | -5.72M | -5.68M | -405.17K | -935.12K | -1.11M | -1.44M |
| Investing Cash Flow | -2,451 | -4,933 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 5.34M | 6.46M | 490.76K | 941.89K | 1.11M | 1.49M |
Propanc Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPCB, the sentiment is Negative. The current price of 1.94 is below the 20-day moving average (MA) of 2.18, below the 50-day MA of 4.57, and below the 200-day MA of 19.75, indicating a bearish trend. The MACD of -0.84 indicates Negative momentum. The RSI at 29.48 is Positive, neither overbought nor oversold. The STOCH value of 69.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPCB.
Propanc Biopharma Risk Analysis
Propanc Biopharma disclosed 51 risk factors in its most recent earnings report. Propanc Biopharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPropanc Biopharma Peers Comparison
Overall Rating
CLRB46Neutral
MBRX44Neutral
NCNA44Neutral
PPCB37Underperform
ONCO33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $11.44M | -0.32 | -154.53% | ― | ― | 66.06% | |
| 44Neutral | $8.26M | -0.67 | -81.19% | ― | ― | 99.02% | |
| 44Neutral | $4.49M | -0.24 | -51.04% | ― | ― | 97.82% | |
| 37Underperform | $2.01M | -0.01 | -239.60% | ― | ― | 98.51% | |
| 33Underperform | $1.89M | -0.04 | -91.95% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PPCB | Propanc Biopharma Inc | 1.94 | -187.01 | -98.97% | |
| CLRB | Cellectar Biosciences Inc | 1.14 | -1.78 | -60.96% | |
| MBRX | Moleculin Biotech | 7.87 | -204.23 | -96.29% | |
| NCNA | Nucana Plc | 0.93 | -2.27 | -70.88% | |
| GNPX | Genprex | 2.08 | -86.80 | -97.66% | |
| ONCO | Onconetix Inc | 3.21 | -1151.79 | -99.72% |
Propanc Biopharma Corporate Events
Propanc Biopharma Appeals Nasdaq Delisting After Bid Shortfall
NegativeOn October 23, 2026, Propanc Biopharma received a notice from Nasdaq’s Listing Qualifications Department stating that the company’s common stock had failed to meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Ma...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
